• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Re: Padeliporfin Vascular-Targeted Photodynamic Therapy versus Active Surveillance in Men with Low-Risk Prostate Cancer (CLIN1001 PCM301): An Open-Label, Phase 3, Randomised Controlled Trial.

作者信息

Taneja Samir S

出版信息

J Urol. 2017 Aug;198(2):255-257. doi: 10.1016/j.juro.2017.05.029. Epub 2017 May 10.

DOI:10.1016/j.juro.2017.05.029
PMID:29370650
Abstract
摘要

相似文献

1
Re: Padeliporfin Vascular-Targeted Photodynamic Therapy versus Active Surveillance in Men with Low-Risk Prostate Cancer (CLIN1001 PCM301): An Open-Label, Phase 3, Randomised Controlled Trial.回复：Padeliporfin 血管靶向光动力疗法与低风险前列腺癌男性主动监测的对比研究（CLIN1001 PCM301）：一项开放标签、3期随机对照试验
J Urol. 2017 Aug;198(2):255-257. doi: 10.1016/j.juro.2017.05.029. Epub 2017 May 10.
2
Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial.帕利泊芬血管靶向光动力疗法与主动监测治疗低危前列腺癌男性患者（CLIN1001 PCM301）：一项开放标签、3 期、随机对照临床试验。
Lancet Oncol. 2017 Feb;18(2):181-191. doi: 10.1016/S1470-2045(16)30661-1. Epub 2016 Dec 20.
3
Commentary on: Padeliporfin Vascular-targeted Photodynamic Therapy Versus Active Surveillance in Men With Low-risk Prostate Cancer (CLIN1001 PCM301): An Open-label, Phase 3, Randomized Controlled Trial.关于“Padeliporfin血管靶向光动力疗法与低风险前列腺癌男性主动监测的对比研究（CLIN1001 PCM301）：一项开放标签、3期、随机对照试验”的评论
Urology. 2017 Jun;104:7-8. doi: 10.1016/j.urology.2017.03.020. Epub 2017 Mar 22.
4
Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer.帕德博芬血管靶向光动力疗法与低风险前列腺癌男性主动监测的对比研究
Lancet Oncol. 2017 Apr;18(4):e187. doi: 10.1016/S1470-2045(17)30170-5.
5
Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer - Authors' reply.帕德立卟吩血管靶向光动力疗法与低风险前列腺癌男性主动监测的对比——作者回复
Lancet Oncol. 2017 Apr;18(4):e188. doi: 10.1016/S1470-2045(17)30163-8.
6
Photodynamic therapy for prostate cancer - A narrative review.光动力疗法治疗前列腺癌——叙述性综述。
Photodiagnosis Photodyn Ther. 2021 Mar;33:102158. doi: 10.1016/j.pdpdt.2020.102158. Epub 2020 Dec 19.
7
Radical Prostatectomy after Vascular Targeted Photodynamic Therapy with Padeliporfin: Feasibility, and Early and Intermediate Results.载培拉滨光动力疗法后行根治性前列腺切除术的可行性，以及早期和中期结果。
J Urol. 2019 Feb;201(2):315-321. doi: 10.1016/j.juro.2018.08.084.
8
Expanding indication of padeliporfin (WST11) vascular-targeted photodynamic therapy: results of prostate cancer Latin-American multicenter study.帕德博芬（WST11）血管靶向光动力疗法的适应证扩展：前列腺癌拉丁美洲多中心研究结果
Actas Urol Esp (Engl Ed). 2018 Dec;42(10):632-638. doi: 10.1016/j.acuro.2018.02.009. Epub 2018 Apr 23.
9
Vascular-targeted photodynamic therapy with TOOKAD® Soluble in localized prostate cancer: standardization of the procedure.使用TOOKAD®可溶性制剂进行的血管靶向光动力疗法治疗局限性前列腺癌：治疗程序的标准化
World J Urol. 2015 Jul;33(7):937-44. doi: 10.1007/s00345-015-1535-2. Epub 2015 Mar 19.
10
Prostate cancer: Light, camera, action - photodynamic therapy for low-risk disease.前列腺癌：灯光、镜头、开拍——低风险疾病的光动力疗法
Nat Rev Urol. 2017 Mar;14(3):134. doi: 10.1038/nrurol.2017.1. Epub 2017 Jan 10.